How much funding has Gallant raised?

Gallant has raised $33.0M in total funding, most recently a Series B round.

Who are Gallant's investors?

Gallant's investors include Digitalis Ventures, Bold Capital Partners, Hill Creek Partners, NovaQuest.

Where is Gallant headquartered?

Gallant is headquartered in San Diego, California, United States.

What industry is Gallant in?

Gallant operates in Biotech, Healthcare.

Gallant

Ready-to-use stem cell therapies for pets.

San Diego, United States · Founded 2018 · $33.0M raised

Biotech

Healthcare

Headquarters: San Diego, California
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: gallant.com
Total Funding: $33.0M
Last Round: $18.0M Series BJun 2025
Rounds: 2

About

Gallant is a San Diego-based animal health biotechnology company redefining veterinary medicine with a pipeline of ready-to-use mesenchymal stem cell therapies derived from uterine tissue. Founded in 2018 by Aaron Hirschhorn, Gallant develops off-the-shelf regenerative therapies targeting inflammatory and degenerative conditions in dogs and cats, including osteoarthritis, feline chronic gingivostomatitis (FCGS), and dermatitis. The company has achieved FDA Technical Section Complete status for Target Animal Safety on its first therapy and operates GallantU, a RACE-approved continuing education platform for veterinary professionals. Gallant's therapies are designed to reduce inflammation, restore function, and fit seamlessly into everyday clinical practice.

Summary

Gallant is a Biotech company based in San Diego, United States, founded in 2018. It has raised $33.0M in total across 2 rounds, most recently a $18.0M Series B round in Jun 2025. Investors include Digitalis Ventures, Bold Capital Partners and Hill Creek Partners.

LinkedIn X (Twitter)